260 related articles for article (PubMed ID: 37675709)
1. Immunotherapy for early-stage non-small cell lung cancer: A system review.
Gao J; Zhang C; Wei Z; Ye X
J Cancer Res Ther; 2023 Aug; 19(4):849-865. PubMed ID: 37675709
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H; Matosevic S; Khalid AB; Durm G; Jalal SI
Front Immunol; 2022; 13():823618. PubMed ID: 35222404
[TBL] [Abstract][Full Text] [Related]
5. Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations.
Sim JK; Choi J; Lee SY
Korean J Intern Med; 2023 Nov; 38(6):787-796. PubMed ID: 37939663
[TBL] [Abstract][Full Text] [Related]
6. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.
Broderick SR
Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant immunotherapy in resectable non-small cell lung cancer.
Lochrin SE; Forde PM
Clin Adv Hematol Oncol; 2023 Aug; (8):415-423. PubMed ID: 37530615
[TBL] [Abstract][Full Text] [Related]
10. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].
Wang S; Mao Y
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy.
Shi Y; Ma X; He D; Dong B; Qiao T
Front Immunol; 2023; 14():1213222. PubMed ID: 37600799
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions.
Saw SP; Ang MK; Tan DS
Curr Treat Options Oncol; 2022 Dec; 23(12):1721-1731. PubMed ID: 36451063
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced (stages III and IV) non-small-cell lung cancer.
Sweeney CJ; Sandler AB
Curr Probl Cancer; 1998; 22(2):85-132. PubMed ID: 9580849
[TBL] [Abstract][Full Text] [Related]
14. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in patients with early stage resectable nonsmall cell lung cancer.
Ghysen K; Vansteenkiste J
Curr Opin Oncol; 2019 Jan; 31(1):13-17. PubMed ID: 30325753
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC).
Merle G; Addeo A
Praxis (Bern 1994); 2023; 112(3):143-147. PubMed ID: 36855884
[No Abstract] [Full Text] [Related]
18. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
[TBL] [Abstract][Full Text] [Related]
19. Platinum versus immunotherapy for early resectable non-small cell lung cancer: A protocol for systematic review and meta analysis.
Tong Z; Luo F; Yang X; Kang M; Lin J
Medicine (Baltimore); 2020 Oct; 99(43):e22349. PubMed ID: 33120735
[TBL] [Abstract][Full Text] [Related]
20. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]